RXi Pharmaceuticals Corp. has entered into a research collaboration with Iovance Biotherapeutics to evaluate potential synergies with RXi’s novel sd-rxRNA therapeutic compounds and Iovance’s autologous cell therapy based on tumor-infiltrating lymphocytes (TILs) for the use in the treatment of cancer. The companies will further investigate and expand the recently published data with TIL and sd-rxRNA products, which demonstrated potentially enhanced tumor killing activity of TIL. ...